Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Activity and Safety of Everolimus in Combination With Octreotide LAR and Metformin in Patients With Advanced Pancreatic Well-differentiated Neuroendocrine Tumors (pWDNETs): a Phase II, Open, Monocentric, Prospective Study

Next Previous
Trial Profile

Activity and Safety of Everolimus in Combination With Octreotide LAR and Metformin in Patients With Advanced Pancreatic Well-differentiated Neuroendocrine Tumors (pWDNETs): a Phase II, Open, Monocentric, Prospective Study

Status: Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 30 Apr 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Everolimus (Primary) ; Metformin; Octreotide
  • Indications Pancreatic cancer; Primitive neuroectodermal tumours
  • Focus Therapeutic Use
  • Acronyms MetNET1

Most Recent Events

  • 03 Sep 2021 Planned End Date changed from 1 Jun 2021 to 1 Oct 2021.
  • 03 Sep 2021 Status changed from recruiting to active, no longer recruiting.
  • 08 Jun 2021 Planned End Date changed from 1 Jun 2017 to 1 Jun 2021.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top